Tanaka Shinji, Arii Shigeki
Department of Hepato-Biliary-Pancreatic Surgery, Tokyo Medical and Dental University, Graduate School of Medicine, 1-5-45 Yushima, Tokyo 113-8519, Japan.
Int J Clin Oncol. 2006 Apr;11(2):82-9. doi: 10.1007/s10147-006-0566-5.
Hepatocellular carcinoma (HCC) is well known as a typical angiogenic tumor, especially in the moderately to poorly differentiated type. Such clinicopathological characteristics are not only useful for imaging diagnosis but are also applicable to the treatment of HCC. In addition, recent molecular studies have revealed that angiogenesis is closely related to hepatocarcinogenesis. In this review, the molecular mechanism of HCC angiogenesis and the antiangiogenic prevention of HCC are reviewed to introduce the latest trends in antiangiogenic treatment of cancers, including HCC.
肝细胞癌（HCC）是一种典型的血管生成性肿瘤，在中低分化型中尤为明显。这种临床病理特征不仅有助于影像学诊断，也适用于HCC的治疗。此外，最近的分子研究表明，血管生成与肝癌发生密切相关。在这篇综述中，我们将对HCC血管生成的分子机制以及HCC的抗血管生成预防进行综述，以介绍包括HCC在内的癌症抗血管生成治疗的最新趋势。
